Pharmaceutical News

RSS

FDA approves ILUMYA for adults with active psoriatic arthritis

Sun Pharmaceutical Industries Limited announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ILUMYA® (tildrakizumab-asmn) for the treatment of adults with active psoriatic arthritis (PsA).

30 Oct 2026

Online reviews reveal troubling side effects of insomnia drug lemborexant

Researchers from Rutgers and other universities analyzed hundreds of online reviews on lemborexant – and learned that about 1 in 4 of the reviewers stopped or planned to stop taking the prescription medication used to treat insomnia.

29 Oct 2026

New framework guides safer obesity drug prescribing in older adults

Today, the American Geriatrics Society (AGS) released a new framework to assist clinicians to safely prescribe obesity medications in older adults.

29 Oct 2026

Thyroid cancer risks and medication timing with oral GLP-1s

Like most prescriptions, glucagon-like peptide 1 (GLP-1) medications to manage weight come with potential risks.

28 Oct 2026

Michigan Medicine study reveals how diabetes drug reduces stroke risk

For millions living with type 2 diabetes, heart disease remains one of the greatest threats to their health.

28 Oct 2026

Breakthrough targeted therapy shows strong precision in treating chronic myeloid leukemia

A more effective and better-tolerated treatment for chronic myeloid leukemia (CML) could improve quality of life for people living with the disease.

27 Oct 2026

Millions get GLP-1 drugs through channels insurance records may miss

Researchers analyzed reports from 9,150 US adults and found that current or previous GLP-1/GIP use rose from 8.2% to 12% between March 2024 and October 2025, largely driven by weight-loss indications. They also estimated that approximately one-third of users obtained treatment through nontraditional channels that standard insurance claims may fail to capture.

26 Oct 2026

Semaglutide changes gut bacteria in rats beyond what eating less explains

Researchers compared semaglutide-treated male and female rats with pair-fed animals receiving the same amount and type of food to distinguish drug-associated microbiome changes from those linked to reduced eating. Semaglutide altered bacterial richness and community composition, with some changes absent from the pair-fed groups and uncertain consequences for health.

26 Oct 2026

Taking a GLP-1 drug? Here's what the safety evidence really shows

A review on GLP-1 receptor agonists highlights risks like pancreatitis and thyroid cancer, emphasizing individual patient risk over general safety concerns.

26 Oct 2026

FDA grants accelerated approval to groundbreaking rectal cancer immunotherapy

A groundbreaking immunotherapy treatment for rectal cancer, developed through pioneering research at Memorial Sloan Kettering Cancer Center (MSK) with critical early-stage funding from Swim Across America, has received accelerated approval from the U.S. Food and Drug Administration (FDA).

22 Oct 2026

Zylidac Bio and Prolific Machines partner to scale Prolific’s next-generation biologics manufacturing platform to GMP production

Zylidac Bio, a fully integrated biologics CDMO within the Zydus Lifesciences Limited (Zydus) group, and Prolific Machines, a biotechnology company advancing biologics development and manufacturing through integrated optogenetics-enabled solutions delivering breakthrough yields, superior on-target quality, and precise process control, today announced a partnership to scale Prolific's platform from early development through GMP production.

From Zylidac Bio LLC 22 Oct 2026

INmune Bio establishes global commercialization framework for Ebstrocel™ through strategic agreement with Uniphar

INmune Bio Inc. (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB).

From INmune Bio 22 Oct 2026

Semaglutide and teduglutide reduce immune-driven gut injury in mice

Researchers found that gut-derived GLP-1 and GLP-2 signaling helped protect mice against T cell-induced intestinal injury, with GLP-1R primarily regulating inflammation and GLP-2R supporting intestinal repair. Semaglutide and teduglutide, administered separately or together, reduced acute intestinal damage in mice lacking intestinal proglucagon, suggesting potential avenues for investigating treatments for immune-mediated gut injury.

21 Oct 2026

ScionxBio announces collaboration to develop long-acting xRNA therapeutics

ScionxBio (the "company", operating as a brand identity of Eleven Therapeutics Ltd. following a horizontal split) a privately held, preclinical-stage biotechnology company pioneering next-generation mRNA therapeutics, distinguished by their extended durability profile, today announced that it has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialize extended exposure versions of certain Sanofi mRNA candidates by leveraging ScionxBio's proprietary TERA® platform.

From ScionxBio 21 Oct 2026

GLP-1 drugs may protect kidney health in people with bipolar disorder

Mayo Clinic researchers found that GLP-1 receptor agonists, medications widely used for diabetes and weight management, were associated with a lower risk of dialysis or kidney transplantation in adults with bipolar disorder and chronic kidney disease.

20 Oct 2026

Study explores potential breast cancer benefits of neurokinin receptor antagonists

Neurokinin receptor (NKR) antagonists are already widely used for treating menopausal hot flashes, representing a highly effective nonhormone treatment.

20 Oct 2026

Blood pressure drug losartan boosts metabolism by stimulating brown fat

Losartan, a drug commonly prescribed for high blood pressure, boosts brown adipose tissue or "brown fat" activity and enhances its metabolism, according to a preclinical study by Weill Cornell Medicine, Rockefeller University and Memorial Sloan Kettering Cancer Center researchers.

19 Oct 2026

Presurgical sleep medications linked to less pain and anxiety after surgery

Improving sleep before surgery through the use of melatonin or Ambien (zolpidem) may ease presurgical anxiety, reduce pain after surgery, decrease opioid requirements and help patients recover better, according to an analysis of 25 years of research presented at the ANESTHESIOLOGY® 2026 annual meeting.

19 Oct 2026

GLP-1 medications linked to reduced postoperative infections and heart complications

GLP-1 medications, widely prescribed for diabetes and weight loss, may also help protect people from serious complications after surgery.

19 Oct 2026

Study identifies priority genes for safer prescribing in older Chinese patients

A research team has identified three genes that could help prioritize pharmacogenomic testing for older adults in China who receive multiple medications.

15 Oct 2026